Cytokinetics, Incorporated’s CYTK share price has surged by 13.20%, which has investors questioning if this is right time to ...

Investing.com -- Shares of Cytokinetics (NASDAQ: NASDAQ: CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% ...

Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

On March 17, analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics, Incorporated (NASDAQ:CYTK ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Cytokinetics (CYTK) Aficamten Promising, Competition a Woe Per the Zacks analyst, a potential approval and successful commercialization of aficamten will be a great boost for Cytokinetics.

Cytokinetics, specializing in muscle biology-directed therapies, is preparing for potential regulatory approvals of its HCM drug candidate, aficamten, following positive results from clinical trials.